Athenex Inc., of Buffalo, N.Y., reported phase II data at the American Academy of Dermatology meeting in San Diego, showing that KX2-391, a dual Src kinase and tubulin polymerization inhibitor, achieved a higher overall 100 percent clearance of actinic keratosis lesions at day 57 in the five-day treatment cohort vs. the three-day treatment cohort (43 percent vs. 32 percent).